Abstract
CardioPharmaGENET COST Action network aims to advance personalized medicine in cardiovascular care by leveraging pharmacogenomics (PGx) to optimize drug therapies. In cardiovascular medicine, this approach is especially critical, given the significant patient variability in drug responses to therapies. The main goal is to establish a pan-European network that addresses several key challenges that hinder the widespread adoption of PGx in cardiovascular care. These challenges include the lack of a centralized knowledge hub for clinicians and policymakers, insufficient integration of PGx into clinical practice, and inconsistent policy frameworks across Europe. The project also seeks to utilize AI and machine learning to streamline the analysis of large-scale genomic data and enhance clinical decision-making. The network includes five working groups (WG) to tackle these issues: WG1 evaluates the current landscape of cardiovascular PGx, identifying key gaps in research, clinical integration, and available resources; WG2 develops optimized guidelines for applying PGx in cardiovascular therapies, focusing on patient stratification based on genetic and demographic profiles; WG3 focuses on advancing digital and AI tools to improve PGx data analysis and implementation in clinical settings; WG4 analyzes regulatory frameworks across Europe, proposing policy changes to facilitate seamless integration of PGx into healthcare systems; WG5 handles communication, dissemination, and stakeholder engagement, ensuring that findings and guidelines are accessible to all stakeholders, including clinicians, researchers, and policymakers. By addressing these challenges, the network will help bridge the gap between PGx research and clinical practice, improving cardiovascular patient outcomes and promoting equitable healthcare access across Europe. This manuscript represents the COST Association-approved Memorandum of Understanding of COST Action CA24165 CardioPharmaGENET.